GLP1R and type 2 diabetes mellitus: We expressed the GLP-1-IgG2σ-Fc fusion protein and tested its bioactivity both in vitro and in vivo in order to investigate whether this represented a potential long-acting GLP-1 receptor agonist for the treatment of T2DM.